The invention is directed to aza-bridged-bicyclic compounds having Formula (I):

$$R_6$$
 R_5
 R_5
 R_5
 R_6
 R_5
 R_6
 R_7
 R_8
 R_8
 R_8
 R_8
 R_8
 R_8
Formula (I)

and pharmaceutically acceptable salts thereof. The compounds are useful $\alpha 4$ integrin receptor antagonists and, in particular, $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.